Close menu




BAYER AG NA O.N.

Photo credits: pixabay.com

Commented by André Will-Laudien on March 19th, 2024 | 06:30 CET

Pay attention now - 100% performance possible with BioNTech, Bayer, Cardiol Therapeutics or HelloFresh

  • Biotechnology
  • Pharma
  • Innovations
  • Food

For investors in the biotech sector, 2024 is starting much like the previous year ended. Everyone is waiting for the big bang, which has yet to materialize. However, now that there is no longer a pandemic and cancer research is still stuck in a rut, selection has become crucial. Investing only in the future is no longer a guarantee of profit; instead, it is much more important to identify the most innovative business models and follow them. BioNTech does not currently have a blockbuster but has a good EUR 17 billion in its coffers. Bayer has seen its share price drop fivefold since 2019, and HelloFresh is also unable to keep its promises. By contrast, Cardiol Therapeutics has experienced a true rally. What lies next here?

Read

Commented by Fabian Lorenz on March 13th, 2024 | 06:30 CET

Bayer disappoints, BioNTech share gives hope, and Cardiol Therapeutics with upside potential!

  • Biotechnology
  • Pharma
  • heartdisease

Analysts were anticipating a more favourable outcome from Bayer's Capital Markets Day. While the spin-off of Aspirin and Co. was expected, and there was also more transparency in the legal disputes, the actual results differed significantly. In some cases, analysts' share price targets plummeted by nearly 50%. In contrast, analysts have renewed their "Buy" recommendation for Cardiol Therapeutics shares. The specialist in cardiovascular diseases is facing exciting weeks and the share could certainly still more than double. There is also movement at BioNTech. In addition to operating figures, there will soon be an update on the drug pipeline. The question remains whether the share can halt its downward trend.

Read

Commented by Stefan Feulner on March 11th, 2024 | 06:30 CET

Novo Nordisk, Defence Therapeutics, Bayer - Rally after the breakout?

  • Biotechnology
  • Pharma
  • Innovations

Biotechnology has been revived after a disappointing stock market year in 2023. In addition to the interest rate cut fantasy, which should benefit the capital-intensive and innovative sector in particular, the current wave of acquisitions should lead to further price rises. Although the broad Nasdaq Biotech Index has only risen by 3% since the beginning of the year, it is currently facing key resistance levels. If these are broken through, the momentum northwards could accelerate.

Read

Commented by Juliane Zielonka on March 1st, 2024 | 17:05 CET

Cardiol Therapeutics, Bayer, Coinbase - Which share will generate profits in the long term?

  • Biotechnology
  • Pharma
  • crypto

The world of pharmaceuticals and life sciences is characterized by precisely documented studies in clinical research. If an active ingredient makes it to approval, there is the potential for a blockbuster worth billions. Cardiol Therapeutics has an active ingredient in the second phase of clinical research for the treatment of heart disease in people under 35 years of age. This active ingredient can also restore the quality of life of 26 million people worldwide who suffer from heart failure. Bayer continues to clean up the unresolved issues left behind by the former CEO. Did the weedkiller RoundUp® from the Monsanto deal possibly lead to improper treatment due to a lack of consumer protection information? The five-figure lawsuits still pending against Roundup are dampening the share's profit prospects. The situation is currently quite different in the cryptocurrency market. Bitcoin is outperforming everyone, and the Coinbase share is benefiting from it. Which investment generates profits in the long term?

Read

Commented by Fabian Lorenz on February 28th, 2024 | 07:45 CET

Strong price targets! Super Micro Computer, Bayer, Almonty Industries

  • Mining
  • Tungsten
  • chemicals
  • AI

Is it time to invest in Super Micro now? Yes, say several experts. Despite the massive price rally, the AI share offers further potential. There are good reasons for this, and the target price is USD 1,300. There are also good reasons for the Almonty Industries share to perform well in 2024 and beyond. The Company focuses on tungsten, a scarce and coveted resource in Europe and North America. Sales and profits are expected to rise sharply, leading to a revaluation of the share. Analysts also see significant potential for Bayer shares. The spin-off of over-the-counter medications, including Aspirin, is expected to drive the share. However, there are some question marks.

Read

Commented by Fabian Lorenz on February 21st, 2024 | 07:00 CET

Top news: BYD, Bayer and Globex Mining

  • Mining
  • Gold
  • Commodities
  • Electromobility
  • chemicals

Bayer shocked investors yesterday with the announcement of its dividend cut, which shouldn't have been much of a surprise. The Company is burdened with high debt, endless legal fines, and an empty pharmaceutical pipeline. In an initial reaction, analysts have lowered the share price target. BYD, on the other hand, is doing well operationally. Only the share price is not picking up. Will a share buyback turn the share price around? For those who want to profit from the commodity boom with reduced risk, then Globex Mining's stock is attractive. The news flow is strong, and those who act quickly can still register and follow the live presentation of the mining incubator at the 10th International Investment Forum, IIF, today.

Read

Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

  • Biotechnology
  • Pharma
  • Innovations

It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.

Read

Commented by André Will-Laudien on February 16th, 2024 | 07:00 CET

MorphoSys and Cardiol Therapeutics in upward mode, while Bayer and Pfizer are in slow mode

  • Biotechnology
  • Pharma

The biotech sector has made a very differentiated start to the new year. While the old favorites are barely moving, the second-line stocks MorphoSys and Cardiol Therapeutics are making a real splash. At Bayer, the bad news just won't go away, and despite a successful major takeover, Pfizer has not yet found its forward gear. After a rally of almost 15% in December, the Nasdaq Biotechnology Index (NBI) has taken a pause in the current year. Now, everyone is waiting for the first interest rate cut by central banks. Inflation is already falling, and the negative economic data for the Eurozone is increasing. The ECB would normally be in demand. What should investors urgently keep an eye on?

Read

Commented by Fabian Lorenz on February 14th, 2024 | 07:00 CET

Plug Power, Bayer, Defense Metals: Shares in panic mode

  • Mining
  • RareEarths
  • Hydrogen
  • Pharma

Is everything not so bad at Plug Power, after all? In January, the hydrogen specialist triggered panic among investors with an announced capital increase. Now, the CEO is suddenly rowing back. So, should one buy the stock now? One analyst advises caution. Bayer shareholders are also in panic mode. The downward trend of the share simply cannot find a bottom. Even at this level, analysts are cautious. Defense Metals, on the other hand, is benefiting from panic - because this concerns the supply of rare earths. The dependence on China is enormous. Defense Metals aims to change this with its rare earth project in Canada. The Company CEO expressed confidence in an interview, stating that an important agreement has been reached with the local population, and important dates are on the horizon.

Read

Commented by Armin Schulz on February 12th, 2024 | 07:00 CET

MorphoSys, Defence Therapeutics, Bayer - Biotech and Pharma suddenly back in focus

  • Biotechnology
  • Pharma

Biotech ETFs have been on the rise since the end of October 2023. German biotech companies were able to raise more funds again last year. There are increasing signs that the tough times for investors in biotech and pharmaceutical companies are over. There is also growing activity on the takeover side. Most recently, the takeover bid from Novartis shifted the focus to companies in the healthcare sector. The Swiss pharmaceutical company wants to acquire MorphoSys for EUR 2.7 billion and thus fill up its oncology pipeline. We have selected three companies from the biotech and pharma sectors and examined their current situation.

Read